Biological treatments in atopic dermatitis

Journal of Clinical Medicine

Volumn 4, Issue 4, 2015, Pages 593-613

  Montes Torres, Andrea ^a   Llamas Velasco, Mar ^a   Pérez Plaza, Alejandra ^a   Solano López, Guillermo ^a   Sánchez Pérez, Javier ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Antibody therapy; Atopic dermatitis; Atopic eczema; Biologics; Pathogenesis

Indexed keywords

ALEFACEPT; CD20 ANTIGEN; CORTICOSTEROID; DUPILUMAB; EFALIZUMAB; IMMUNOGLOBULIN E; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 3; INTERLEUKIN 31; INTERLEUKIN 4; INTERLEUKIN 5; LIGELIZUMAB; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MEPOLIZUMAB; OMALIZUMAB; PITRAKINRA; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; THYMIC STROMAL LYMPHOPOIETIN; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB;

ASTHMA; ATOPIC DERMATITIS; BIOLOGICAL THERAPY; CYTOLYSIS; DRUG EFFICACY; GENE EXPRESSION; HEADACHE; HUMAN; INJECTION SITE REACTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SKIN DEFECT; SYSTEMATIC REVIEW (TOPIC); URTICARIA;

EID: 85048751315     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm4040593     Document Type: Review

References (102)

1. Garnacho-Saucedo, G.; Salido-Vallejo, R.; Moreno-Giménez, J.C. Actualización en dermatitis atópica. Propuesta de algoritmo de actuación. Actas Dermosifiliogr. 2013, 104, 4–16.
2. Ortiz de Frutos, F.J.; Torrelo, A.; de Lucas, R.; Gonzalez, M.A.; Alomar, A.; Vera, A.; Ros, S.; Mora, A.M.; Cuervo, J. Patient perspectives on triggers, adherence to medical recommendations, and disease control in atopic dermatitis: The DATOP study. Actas Dermosifiliogr. 2014, 105, 487–496.
3. Ibler, K.S.; Jemec, G.B. Novel investigational therapies for atopic dermatitis. Expert Opin. Investig. Drugs2015, 24, 61–68.
4. Flohr, C.; Mann, J. New insights into the epidemiology of childhood atopic dermatitis. Allergy2014, 69, 3–16.
5. Harskamp, C.T.; Armstrong, A.W. Immunology of atopic dermatitis: Novel insights into mechanisms and immunomodulatory therapies. Semin. Cutan. Med. Surg. 2013, 32, 132–139.
6. Leung, D.Y.M.; Boguniewicz, M.; Howell, M.D.; Nomura, I.; Hamid, Q.A. New insights into atopic dermatitis. J. Clin. Investig. 2004, 113, 651–657.
7. Eichenfield, L.F.; Tom, W.L.; Chamlin, S.L.; Feldman, S.R.; Hanifin, J.M.; Simpson, E.L.; Berger, T.G.; Bergman, J.N.; Cohen, D.E.; Cooper, K.D.; et al. Guidelines of care for the management of atopic dermatitis: Section 1. Diagnosis and assessment of atopic dermatitis. J. Am. Acad. Dermatol. 2014, 70, 338–351.
8. Thomsen, S.F. Atopic dermatitis: Natural history, diagnosis, and treatment. ISRN Allergy2014, 2014, doi:10.1155/2014/354250.
9. Wolter, S.; Price, H.N. Atopic dermatitis. Pediatr. Clin. North Am. 2014, 61, 241–260.
10. Auriemma, M.; Vianale, G.; Amerio, P.; Reale, M. Cytokines and T cells in atopic dermatitis. Eur. Cytokine Netw. 2013, 24, 37–44.
11. Brandt, E.B.; Sivaprasad, U. Th2 cytokines and atopic dermatitis. J. Clin. Cell. Immunol. 2011, 2, doi:10.4172/2155-9899.1000110.
12. Gittler, J.K.; Shemer, A.; Suarez-Farinas, M.; Fuentes-Duculan, J.; Gulewicz, K.J.; Wang, C.Q.; Mitsui, H.; Cardinale, I.; de Guzman Strong, C.; Krueger, J.G.; et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J. Allergy Clin. Immunol. 2012, 130, 1344–1354.
13. Walling, H.W.; Swick, B.L. Update on the management of chronic eczema: New approaches and emerging treatment options. Clin. Cosmet. Investig. Dermatol. 2010, 28, 99–117.
14. Schmitt, J.; Schakel, K.; Schmitt, N.; Meurer, M. Systemic treatment of severe atopic eczema: A systematic review. Acta Derm. Venereol. 2007, 87, 100–111.
15. Belloni, B.; Andres, C.; Ollert, M.; Ring, J.; Mempel, M. Novel immunological approaches in the treatment of atopic eczema. Curr. Opin. Allergy Clin. Immunol. 2008, 8, 423–427.
16. Fernández Vozmediano, J.M.; Armario Hita, J.C. Nuevas perspectivas terapéuticas en dermatitis atópica. Med. Cutan. Iber. Lat. Am. 2011, 39, 30–36.
17. Numerof, R.P.; Asadullah, K. Cytokine and anti-cytokine therapies for psoriasis and atopic dermatitis. BioDrugs2006, 20, 93–103.
18. Bennett, D.D.; Ohanian, M.; Cable, C.T. Rituximab in severe skin diseases: Target, disease, and dose. Clin. Pharmacol. 2010, 2, 135–141.
19. Makris, M.P.; Papadavid, E.; Zuberbier, T. The use of biologicals in cutaneous allergies-present and future. Curr. Opin. Allergy Clin. Immunol. 2014, 14, 409–416.
20. Nagel, A.; Hertl, M.; Eming, R. B-cell-directed therapy for inflammatory skin diseases. J. Investig. Dermatol. 2009, 129, 289–301.
21. España, A.; Ornilla, E.; Panizo, C. Rituximab en dermatología. Actas Dermosifiliogr. 2013, 104, 380–392.
22. Simon, D.; Hosli, S.; Kostylina, G.; Yawalkar, N.; Simon, H.U. Anti-CD20 (rituximab) treatment improves atopic eczema. J. Allergy Clin. Immunol. 2008, 121, 122–128.
23. Ponte, P.; Lopes, M.J. Apparent safe use of single dose rituximab for recalcitrant atopic dermatitis in the first trimester of a twin pregnancy. J. Am. Acad. Dermatol. 2010, 63, 355–356.
24. Sediva, A.; Kayserova, J.; Vernerova, E.; Polouckova, A.; Capkova, S.; Spisek, R.; Bartunkova, J. Anti-CD20 (rituximab) treatment for atopic eczema. J. Allergy Clin. Immunol. 2008, 121, 1515–1516.
25. Fernández-Antón Martínez, M.C.; Leis-Dosil, V.; Alfageme-Roldán, F.; Paravisini, A.; Sánchez-Ramón, S.; Suárez Fernández, R. Omalizumab for the treatment of atopic dermatitis. Actas Dermosifiliogr. 2012, 103, 624–628.
26. Forman, S.B.; Garrett, A.B. Success of omalizumab as monotherapy in adult atopic dermatitis: Case report and discussion of the high-affinity immunoglobulin E receptor, FcepsilonRI. Cutis2007, 80, 38–40.
27. Liu, F.T.; Goodarzi, H.; Chen, H.Y. IgE, mast cells, and eosinophils in atopic dermatitis. Clin. Rev. Allergy Immunol. 2011, 41, 298–310.
28. Prussin, C.; Griffith, D.T.; Boesel, K.M.; Lin, H.; Foster, B.; Casale, T.B. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J. Allergy Clin. Immunol. 2003, 112, 1147–1154.
29. European Medicines Agency. Available online: http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Summary_for_the_public/human/000606/WC500057293.pdf (accessed on 20 December 2014).
30. Sheinkopf, L.E.; Rafi, A.W.; Do, L.T.; Katz, R.M.; Klaustermeyer, W.B. Efficacy of omalizumab in the treatment of atopic dermatitis: A pilot study. Allergy Asthma Proc. 2008, 29, 530–537.
31. Kim, D.H.; Park, K.Y.; Kim, B.J.; Kim, M.N.; Mun, S.K. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin. Exp. Dermatol. 2013, 38, 496–500.
32. Lane, J.E.; Cheyney, J.M.; Lane, T.N.; Kent, D.E.; Cohen, D.J. Treatment of recalcitrant atopic dermatitis with omalizumab. J. Am. Acad. Dermatol. 2006, 54, 68–72.
33. Belloni, B.; Ziai, M.; Lim, A.; Lemercier, B.; Sbornik, M.; Weidinger, S.; Andres, C.; Schnopp, C.; Ring, J.; Hein, R.; et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J. Allergy Clin. Immunol. 2007, 120, 1223–1225.
34. Heil, P.M.; Maurer, D.; Klein, B.; Hultsch, T.; Stingl, G. Omalizumab therapy in atopic dermatitis: Depletion of IgE does not improve the clinical course—A randomized, placebo-controlled and double blind pilot study. J. Dtsch. Dermatol. Ges. 2010, 8, 990–998.
35. Krathen, R.A.; Hsu, S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J. Am. Acad. Dermatol. 2005, 53, 338–340.
36. Clinicaltrials.gov. Role of Anti-IgE in Severe Childhood Eczema (ADAPT). Available online: https://www.clinicaltrials.gov/ct2/show/NCT02300701 (accessed on 20 December 2014).
37. Iyengar, S.R.; Hoyte, E.G.; Loza, A.; Bonaccorso, S.; Chiang, D.; Umetsu, D.T.; Nadeau, K.C. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: A randomized, placebo controlled clinical trial. Int. Arch. Allergy Immunol. 2013, 162, 89–93.
38. Clinicaltrials.gov. Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients. Available online: https://www.clinicaltrials.gov/ct2/show/NCT01552629 (accessed on 20 December 2014).
39. Jensen, L.E. Targeting the IL-1 family members in skin inflammation. Curr. Opin. Investig. Drugs2010, 11, 1211–1220.
40. Krause, K.; Metz, M.; Makris, M.; Zuberbier, T.; Maurer, M. The role of interleukin-1 in allergy-related disorders. Curr. Opin. Allergy Clin. Immunol. 2012, 12, 477–484.
41. Neven, B.; Marvillet, I.; Terrada, C.; Ferster, A.; Boddaert, N.; Couloignier, V.; Pinto, G.; Pagnier, A.; Bodemer, C.; Bodaghi, B.; et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 2010, 6, 258–267.
42. Abramovits, W.; Rivas Bejarano, J.J.; Valdecantos, W.C. Role of interleukin 1 in atopic dermatitis. Dermatol. Clin. 2013, 31, 437–444.
43. Clinicaltrials.gov. A Pilot Study Using Anakinra/Kineret for the Treatment of Patients with Severe Atopic Dermatitis. Available online: https://www.clinicaltrials.gov/ct2/show/NCT01122914 (accessed on 20 December 2014).
44. Vatrella, A.; Fabozzi, I.; Calabrese, C.; Maselli, R.; Pelaia, G. Dupilumab: A novel treatment for asthma. J. Asthma Allergy2014, 7, 123–130.
45. Reichert, J.M. Antibodies to watch in 2014: Mid-year update. MAbs2014, 6, 799–802.
46. Wenzel, S.; Ford, L.; Pearlman, D.; Spector, S.; Sher, L.; Skobieranda, F.; Wang, L.; Kirkesseli, S.; Rocklin, R.; Bock, B.; et al. Dupilumab in persistent asthma with elevated eosinophil levels. N. Engl. J. Med. 2013, 368, 2455–2466.
47. Di Lernia, V. Therapeutic strategies in extrinsic atopic dermatitis: Focus on inhibition of IL-4 as a new pharmacological approach. Expert Opin. Ther. Targets2015, 19, 87–96.
48. Beck, L.A.; Thaci, D.; Hamilton, J.D.; Graham, N.M.; Bieber, T.; Rocklin, R.; Ming, J.E.; Ren, H.; Kao, R.; Simpson, E.; et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N. Engl. J. Med. 2014, 371, 130–139.
49. Clinicaltrials.gov. Open-Label Study of Dupilumab (REGN668/SAR231893) in Patients with Atopic Dermatitis. Available online: https://www.clinicaltrials.gov/ct2/show/NCT01949311 (accessed on 20 December 2014).
50. Clinicaltrials.gov. Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients with Moderate-to-Severe Atopic Dermatitis. Available online: https://www.clinicaltrials.gov/ct2/show/NCT02277769 (accessed on 20 December 2014).
51. Clinicaltrials.gov. Study to Assess the Efficacy and Long-Term Safety of Dupilumab (REGN668/SAR231893) in Adult Patients with Moderate-to-Severe Atopic Dermatitis. Available online: https://www.clinicaltrials.gov/ct2/show/NCT02260986 (accessed on 20 December 2014).
52. Hambly, N.; Nair, P. Monoclonal antibodies for the treatment of refractory asthma. Curr. Opin. Pulm. Med. 2014, 20, 87–94.
53. Antoniu, S.A. Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema. Curr. Opin. Investig. Drugs2010, 11, 1286–1294.
54. Clinicaltrials.gov. A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects with Atopic Eczema. Available online: https://www.clinicaltrials.gov/ct2/show/NCT00676884 (accessed on 20 December 2014).
55. Smith, D.A.; Minthorn, E.A.; Beerahee, M. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin. Pharmacokinet. 2011, 50, 215–227.
56. Menzies-Gow, A.; Ying, S.; Phipps, S.; Kay, A.B. Interactions between eotaxin, histamine and mast cells in early microvascular events associated with eosinophil recruitment to the site of allergic skin reactions in humans. Clin. Exp. Allergy2004, 34, 1276–1282.
57. Molfino, N.A.; Gossage, D.; Kolbeck, R.; Parker, J.M.; Geba, G.P. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin. Exp. Allergy2012, 42, 712–737.
58. Corren, J. Inhibition of interleukin-5 for the treatment of eosinophilic diseases. Discov. Med. 2012, 13, 305–312.
59. Oldhoff, J.M.; Darsow, U.; Werfel, T.; Katzer, K.; Wulf, A.; Laifaoui, J.; Hijnen, D.J.; Plotz, S.; Knol, E.F.; Kapp, A.; et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy2005, 60, 693–696.
60. Fernández-Antón Martínez, M.C.; Alfageme Roldán, F.; Ciudad Blanco, C.; Suárez Fernández, R. Ustekinumab in the treatment of severe atopic dermatitis: A preliminary report of our experience with 4 patients. Actas Dermosifiliogr. 2014, 105, 312–313.
61. Agusti-Mejias, A.; Messeguer, F.; Garcia, R.; Febrer, I. Severe refractory atopic dermatitis in an adolescent patient successfully treated with ustekinumab. Ann. Dermatol. 2013, 25, 368–370.
62. Puya, R.; Alvarez-López, M.; Velez, A.; Casas Asuncion, E.; Moreno, J.C. Treatment of severe refractory adult atopic dermatitis with ustekinumab. Int. J. Dermatol.2012, 51, 115–116.
63. Dhingra, N.; Guttman-Yassky, E. A possible role for IL-17A in establishing Th2 inflammation in murine models of atopic dermatitis. J. Investig. Dermatol. 2014, 134, 2071–2074.
64. Batista, D.I.; Perez, L.; Orfali, R.L.; Zaniboni, M.C.; Samorano, L.P.; Pereira, N.V.; Sotto, M.N.; Ishizaki, A.S.; Oliveira, L.M.; Sato, M.N.; et al. Profile of skin barrier proteins (filaggrin, claudins 1 and 4) and Th1/Th2/Th17 cytokines in adults with atopic dermatitis. J. Eur. Acad. Dermatol. Venereol. 2014, doi:10.1111/jdv.12753.
65. Toda, M.; Leung, D.Y.; Molet, S.; Boguniewicz, M.; Taha, R.; Christodoulopoulos, P.; Fukuda, T.; Elias, J.A.; Hamid, Q.A. Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J. Allergy Clin. Immunol. 2003, 111, 875–881.
66. Koga, C.; Kabashima, K.; Shiraishi, N.; Kobayashi, M.; Tokura, Y. Possible pathogenic role of Th17 cells for atopic dermatitis. J. Investig. Dermatol. 2008, 128, 2615–2630.
67. Clinicaltrials.gov. Pilot Study of Ustekinumab for Subjects with Chronic Atopic Dermatitis. Available online: https://www.clinicaltrials.gov/ct2/show/NCT01806662 (accessed on 22 December 2014).
68. Clinicaltrials.gov. A Study of Ustekinumab (STELARA®) in Adult Japanese Participants with Severe Atopic Dermatitis. Available online: https://www.clinicaltrials.gov/ct2/show/NCT01945086 (accessed on 22 December 2014).
69. Nograles, K.E.; Zaba, L.C.; Shemer, A.; Fuentes-Duculan, J.; Cardinale, I.; Kikuchi, T.; Ramon, M.; Bergman, R.; Krueger, J.G.; Guttman-Yassky, E. IL-22-producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J. Allergy Clin. Immunol. 2009, 123, 1244–1252.
70. Clinicaltrials.gov. Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis. Available online: https://www.clinicaltrials.gov/ct2/show/NCT01941537 (accessed on 22 December 2014).
71. Grimstad, O.; Sawanobori, Y.; Vestergaard, C.; Bilsborough, J.; Olsen, U.B.; Grønhøj-Larsen, C.; Matsushima, K. Anti-interleukin-31 antibodies ameliorate scratching behaviour in NC/Nga mice: A model of atopic dermatitis. Exp. Dermatol. 2009, 18, 35–43.
72. Dillon, S.R.; Sprecher, C.; Hammond, A.; Bilsborough, J.; Rosenfeld-Franklin, M.; Presnell, S.R.; Haugen, H.S.; Maurer, M.; Harder, B.; Johnston, J.; et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat. Immunol. 2004, 5, 752–760.
73. Nobbe, S.; Dziunycz, P.; Mühleisen, B.; Bilsborough, J.; Dillon, S.R.; French, L.E.; Hofbauer, G.F. IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis. Acta Derm. Venereol. 2012, 92, 24–28.
74. Kasutani, K.; Fujii, E.; Ohyama, S.; Adachi, H.; Hasegawa, M.; Kitamura, H.; Yamashita, N. Anti-IL-31 receptor antibody is shown to be a potential therapeutic option for treating itch and dermatitis in mice. Br. J. Pharmacol. 2014, 171, 5049–5058.
75. Clinicaltrials.gov. A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults with Atopic Dermatitis. Available online: https://www.clinicaltrials.gov/ct2/show/NCT01614756 (accessed on 22 December 2014).
76. Clinicaltrials.gov. A Phase 2 Study of CIM331 for Atopic Dermatitis Patients. Available online: https://www.clinicaltrials.gov/ct2/show/NCT01986933 (accessed on 22 December 2014).
77. Baniandrés, O.; Pulido, A.; Silvente, C.; Suárez, R.; Lázaro, P. Clinical outcomes in patients with psoriasis following discontinuation of efalizumab due to suspension of marketing authorization. Actas Dermosifiliogr. 2010, 101, 421–427.
78. Weinberg, J.M.; Siegfried, E.C. Successful treatment of severe atopic dermatitis in a child and an adult with T-cell modulator efalizumab. Arch. Dermatol. 2006, 142, 555–558.
79. Takiguchi, R.; Tofte, S.; Simpson, B.; Harper, E.; Blauvelt, A.; Hanifin, J.; Simpson, E. Efalizumab for severe atopic dermatitis: A pilot study in adults. J. Am. Acad. Dermatol. 2007, 56, 222–227.
80. Chacko, M.; Weinberg, J.M. Efalizumab. Dermatol. Ther. 2007, 20, 265–269.
81. Ohmura, T.; Konomi, A.; Satoh, Y.; Hayashi, T.; Tsunenari, I.; Kadota, T.; Panzenbeck, M.J.; Satoh, H. Suppression of atopic-like dermatitis by treatment with antibody to lymphocyte function-associated antigen-1 in NC/Nga mouse. Eur. J. Pharmacol. 2004, 504, 113–117.
82. Ibler, K.; Dam, T.N.; Gniadecki, R.; Kragballe, K.; Jemec, G.B.; Agner, T. Efalizumab for severe refractory atopic eczema: Retrospective study on 11 cases. J. Eur. Acad. Dermatol. Venereol. 2010, 24, 837–839.
83. Bovenschen, H.J.; Gerritsen, W.J.; de Jong, E.M.; van de Kerkhof, P.C. Addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis. Acta Derm. Venereol. 2006, 86, 281–282.
84. Simon, D.; Wittwer, J.; Kostylina, G.; Buettiker, U.; Simon, H.U.; Yawalkar, N. Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema. J. Allergy Clin. Immunol. 2008, 122, 423–424.
85. Moul, D.K.; Routhouska, S.B.; Robinson, M.R.; Korman, N.J. Alefacept for moderate to severe atopic dermatitis: A pilot study in adults. J. Am. Acad. Dermatol. 2008, 58, 984–989.
86. Buka, R.L.; Resh, B.; Roberts, B.; Cunningham, B.B.; Friedlander, S. Etanercept minimally effective in 2 children with atopic dermatitis. J. Am. Acad. Dermatol. 2005, 53, 358–359.
87. Jacobi, A.; Antoni, C.; Manger, B.; Schuler, G.; Hertl, M. Infliximab in the treatment of moderate to severe atopic dermatitis. J. Am. Acad. Dermatol. 2005, 52, 522–526.
88. Lebas, D.; Staumont-Sallé, D.; Solau-Gervais, E.; Flipo, R.M.; Delaporte, E. Cutaneous manifestations during treatment with TNF-alpha blockers: 11 cases. Ann. Dermatol. Venereol. 2007, 134, 337–342.
89. Mangge, H.; Gindl, S.; Kenzian, H.; Schauenstein, K. Atopic dermatitis as a side effect of anti-tumor necrosis factor-alpha therapy. J. Rheumatol.2003, 30, 2506–2507.
90. Ruiz-Villaverde, R.; Galán-Gutierrez, M. Exacerbation of atopic dermatitis in a patient treated with infliximab. Actas Dermosifiliogr. 2012, 103, 743–746.
91. Rullan, P.; Murase, J. Two cases of chronic atopic dermatitis treated with soluble tumor necrosis factor receptor therapy. J. Drug Dermatol. 2009, 8, 873–876.
92. Maini, R.N.; Breedveld, F.C.; Kalden, J.R.; Smolen, J.S.; Davis, D.; Macfarlane, J.D.; Antoni, C.; Leeb, B.; Elliott, M.J.; Woody, J.N.; et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998, 41, 1552–1563.
93. Vermeire, S.; Noman, M.; van Assche, G.; Baert, F.; D’Haens, G.; Rutgeerts, P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut2007, 56, 1226–1231.
94. Cassano, N.; Loconsole, F.; Coviello, C.; Vena, G.A. Infliximab in recalcitrant severe atopic eczema associated with contact allergy. Int. J. Immunopathol. Pharmacol. 2006, 19, 237–240.
95. Yayli, S.; Irla, N.; Yawalkar, N. Adalimumab in recalcitrant severe psoriasis associated with atopic dermatitis. Case Rep. Dermatol. 2013, 5, 332–335.
96. Kubo, T.; Kamekura, R.; Kumagai, A.; Kawata, K.; Yamashita, K.; Mitsuhashi, Y.; Kojima, T.; Sugimoto, K.; Yoneta, A.; Sumikawa, Y.; et al.DeltaNp63 controls a TLR3-mediated mechanism that abundantly provides thymic stromal lymphopoietin in atopic dermatitis. PLoS ONE2014, 9, e105498.
97. Han, N.R.; Moon, P.D.; Kim, H.M.; Jeong, H.J. Tryptanthrin ameliorates atopic dermatitis through down-regulation of TSLP. Arch. Biochem. Biophys. 2014, 542, 14–20.
98. Soumelis, V.; Reche, P.A.; Kanzler, H.; Yuan, W.; Edward, G.; Homey, B.; Gilliet, M.; Ho, S.; Antonenko, S.; Lauerma, A.; et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat. Immunol. 2002, 3, 673–680.
99. Lee, E.B.; Kim, K.W.; Hong, J.Y.; Jee, H.M.; Sohn, M.H.; Kim, K.E. Increased serum thymic stromal lymphopoietin in children with atopic dermatitis. Pediatr. Allergy Immunol. 2010, 21, e457–e460.
100. Clinicaltrials.gov. Safety Study of AMG 157 in Healthy Subjects and Subjects with Atopic Dermatitis. Available online: https://www.clinicaltrials.gov/ct2/show/NCT00757042 (accessed on 28 February 2015).
101. Arm, J.P.; Bottoli, I.; Skerjanec, A.; Floch, D.; Groenewegen, A.; Maahs, S.; Owen, C.E.; Jones, I.; Lowe, P.J. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin. Exp. Allergy2014, 44, 1371–1385.
102. Gauvreau, G.M.; O’Byrne, P.M.; Boulet, L.P.; Wang, Y.; Cockcroft, D.; Bigler, J.; Fitzgerald, J.M.; Boedigheimer, M.; Davis, B.E.; Dias, C.; et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N. Engl. J. Med. 2014, 370, 2102–2110.